重药控股
(000950)
| 流通市值：95.57亿 | | | 总市值：95.57亿 |
| 流通股本：17.28亿 | | | 总股本：17.28亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 59,692,657,955.53 | 39,779,227,702.93 | 19,624,282,945.17 | 80,119,107,345.07 |
| 营业收入 | 59,692,657,955.53 | 39,779,227,702.93 | 19,624,282,945.17 | 80,119,107,345.07 |
| 二、营业总成本 | 59,058,434,322.35 | 39,271,948,454.85 | 19,384,577,382.4 | 79,031,580,193.45 |
| 营业成本 | 55,254,372,237.51 | 36,688,624,034.36 | 18,103,470,070.75 | 73,810,392,559.11 |
| 税金及附加 | 141,878,948.79 | 100,812,118.49 | 42,941,871.55 | 218,858,823.94 |
| 销售费用 | 1,708,321,550.29 | 1,130,619,314 | 556,935,266.19 | 2,213,468,627 |
| 管理费用 | 1,131,475,000.09 | 799,736,099.79 | 423,197,099.18 | 1,486,448,485.75 |
| 研发费用 | 8,576,219.24 | 7,050,736.95 | 199,371.05 | 383,333.1 |
| 财务费用 | 813,810,366.43 | 545,106,151.26 | 257,833,703.68 | 1,302,028,364.55 |
| 其中:利息费用 | 861,134,770.5 | 576,856,196.22 | 272,482,546.01 | 1,340,086,164.36 |
| 其中:利息收入 | 70,254,237.69 | 47,382,746.06 | 22,832,949.88 | 91,725,401.62 |
| 加:公允价值变动收益 | 7,047,508.39 | 8,905,917.98 | 9,617,562.64 | 16,162,257.06 |
| 加:投资收益 | 241,919,054.21 | 163,900,452.5 | 86,719,317.32 | 301,547,684.07 |
| 资产处置收益 | 1,135,849.98 | 1,158,138.14 | 1,063,097.97 | 788,757.36 |
| 资产减值损失(新) | -9,788,650.84 | -89,714.27 | -98,549.48 | -27,756,422.5 |
| 信用减值损失(新) | -353,321,296.54 | -260,490,241.66 | -172,573,403.93 | -440,498,664.69 |
| 其他收益 | 26,853,372.65 | 21,862,311.09 | 8,700,258.42 | 69,324,070.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 548,069,471.03 | 442,526,111.86 | 173,133,845.71 | 1,007,094,833.12 |
| 加:营业外收入 | 20,117,320.41 | 13,820,736.19 | 3,087,390.66 | 32,776,095.21 |
| 减:营业外支出 | 21,105,429.92 | 10,254,641.98 | 1,484,807.23 | 31,330,232.3 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 547,081,361.52 | 446,092,206.07 | 174,736,429.14 | 1,008,540,696.03 |
| 减:所得税费用 | 140,237,633.89 | 103,386,763.93 | 39,973,501.64 | 236,041,618.02 |
| 六、净利润 | 406,843,727.63 | 342,705,442.14 | 134,762,927.5 | 772,499,078.01 |
| 持续经营净利润 | 406,843,727.63 | 342,705,442.14 | 134,762,927.5 | 772,499,078.01 |
| 归属于母公司股东的净利润 | 292,225,609 | 238,088,559.78 | 102,960,760.48 | 654,956,871.96 |
| 少数股东损益 | 114,618,118.63 | 104,616,882.36 | 31,802,167.02 | 117,542,206.05 |
| (一)基本每股收益 | 0.17 | 0.14 | 0.06 | 0.38 |
| (二)稀释每股收益 | 0.17 | 0.14 | 0.06 | 0.38 |
| 八、其他综合收益 | -269,117.69 | -652,446.21 | - | -41,479,914.34 |
| 归属于母公司股东的其他综合收益 | -227,271.21 | -550,994.02 | - | -41,029,966.34 |
| 九、综合收益总额 | 406,574,609.94 | 342,052,995.93 | 134,762,927.5 | 731,019,163.67 |
| 归属于母公司股东的综合收益总额 | 291,998,337.79 | 237,537,565.76 | 102,960,760.48 | 613,926,905.62 |
| 归属于少数股东的综合收益总额 | 114,576,272.15 | 104,515,430.17 | 31,802,167.02 | 117,092,258.05 |
| 公告日期 | 2024-10-25 | 2024-08-21 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |